Sigyn Therapeutics, INC 8-K filings

Sigyn Therapeutics, Inc. entered into a convertible note purchase agreement for up to $550,000 while three directors resigned due to lapsed D&O insurance.

Sigyn Therapeutics announces the retirement of its CFO, provides a business update including a letter from the CEO addressing emerging pandemic threats, and releases an investor presentation.

Sigyn Therapeutics has appointed Michael Ryan, a seasoned executive and investor, to its Board of Directors, effective January 11, 2025.

Sigyn Therapeutics has amended its corporate charter to decrease the number of authorized common stock shares to 100 million, while keeping preferred stock authorizations unchanged.

Sigyn Therapeutics exchanged 246,259 stock purchase warrants for 184,699 restricted shares of common stock, eliminating all outstanding warrants.

Sigyn Therapeutics filed an amendment to a previous 8-K report to correct an error regarding the control of sellers in a recent share issuance.

Sigyn Therapeutics converted $474,793 of debentures into 118,700 shares of common stock, increasing the total outstanding shares to 1,420,678.

Sigyn Therapeutics converted $226,903 of debentures into 37,820 common shares, increasing the total outstanding shares to 1,263,653.

Sigyn Therapeutics has submitted a Patent Cooperation Treaty application for its ImmunePrepTM platform, designed to improve the delivery of immunotherapeutic antibodies for cancer treatment.

Sigyn Therapeutics converted a significant portion of its convertible debentures into Series B Preferred Stock and extended the maturity dates on the remaining debentures.

Sigyn Therapeutics has announced the effectiveness of a 1-for-40 reverse stock split, which will temporarily change the company's stock symbol.

Sigyn Therapeutics has enacted a 1-for-40 reverse stock split, effective January 31, 2024, to consolidate its outstanding shares.

Sigyn Therapeutics has entered into a Share Surrender Agreement with its Chief Technical Officer, resulting in the cancellation of 2,564,000 shares and an updated total of 48,972,602 outstanding shares.